Render Target: SSR
Render Timestamp: 2024-12-26T18:46:17.569Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-09-20 06:23:28.087
Product last modified at: 2024-12-17T18:58:23.535Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72

Mithramycin A #61471

    Product Information

    Product Usage Information

    Mithramycin A is supplied as a lyophilized powder. For a 1 mM stock, reconstitute 1 mg of powder in 0.92 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.

    Storage

    Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 1085.2 g/mol
    Purity >98%
    Molecular Formula C52H76O24
    CAS 18378-89-7
    Solubility Soluble in DMSO at 20 mg/mL or ethanol at 10 mg/mL.

    Background

    Mithramycin A is an antibiotic that binds the minor groove in GC-rich regions of DNA to inhibit transcription factor-DNA binding and prevent transcriptional activation (1). Mithramycin A is a specific inhibitor of specificity protein 1 (SP1), a ubiquitously expressed transcription factor that plays a role in control of cell growth and differentiation, apoptosis, and the immune response (2). Inhibition of SP1 by Mithramycin A leads to suppression of downstream targets, including proto-oncogenes ha-RAS12 and c-Myc13, anti-apoptotic genes survivin14 and XIAP15, and the pro-angiogenic gene VEGF. Mithramycin A inhibition of SP1 suppresses anti-apoptotic gene expression and induces caspase-dependent apoptosis (3). Several studies demonstrated that nanomolar concentrations of Mithramycin A could suppress tumor growth with no apparent effect on normal cell division. Mithramycin A was used therapeutically to treat testicular cancer and myeloid leukemia. Additional work suggests a possible role of Mithramycin A in treating cervical and colorectal cancer (4).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.